Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.

Berg MG, Adams RJ, Gambhira R, Siracusa MC, Scott AL, Roden RB, Ketner G.

Clin Vaccine Immunol. 2014 Sep;21(9):1224-31. doi: 10.1128/CVI.00197-14. Epub 2014 Jul 2.

2.

Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.

Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.

Virol J. 2015 Sep 11;12:140. doi: 10.1186/s12985-015-0364-7.

3.

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.

Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.

Clin Vaccine Immunol. 2007 Oct;14(10):1285-95. Epub 2007 Aug 8.

4.

Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.

Monroy-García A, Gómez-Lim MA, Weiss-Steider B, Hernández-Montes J, Huerta-Yepez S, Rangel-Santiago JF, Santiago-Osorio E, Mora García Mde L.

Arch Virol. 2014 Feb;159(2):291-305. doi: 10.1007/s00705-013-1819-z. Epub 2013 Aug 29.

PMID:
23990055
5.

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.

Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.

J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.

6.

Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.

Kines RC, Zarnitsyn V, Johnson TR, Pang YY, Corbett KS, Nicewonger JD, Gangopadhyay A, Chen M, Liu J, Prausnitz MR, Schiller JT, Graham BS.

PLoS One. 2015 Mar 18;10(3):e0120797. doi: 10.1371/journal.pone.0120797. eCollection 2015.

7.

A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.

Tumban E, Peabody J, Peabody DS, Chackerian B.

PLoS One. 2011;6(8):e23310. doi: 10.1371/journal.pone.0023310. Epub 2011 Aug 17.

8.

HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice.

Berg M, Gambhira R, Siracusa M, Hoiczyk E, Roden R, Ketner G.

Vaccine. 2007 Apr 30;25(17):3501-10. Epub 2006 Jul 18.

PMID:
16914239
9.

VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.

Bolhassani A, Shirbaghaee Z, Agi E, Davoudi N.

Protein Expr Purif. 2015 Dec;116:7-11. doi: 10.1016/j.pep.2015.08.024. Epub 2015 Aug 21.

PMID:
26304732
10.

Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine.

Xu D, Wang D, Yang X, Cao M, Yu J, Wang Y.

Antiviral Res. 2014 Feb;102:61-9. doi: 10.1016/j.antiviral.2013.12.003. Epub 2013 Dec 13.

PMID:
24333518
11.

Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.

Nieto K, Stahl-Hennig C, Leuchs B, Müller M, Gissmann L, Kleinschmidt JA.

Hum Gene Ther. 2012 Jul;23(7):733-41. doi: 10.1089/hum.2011.202. Epub 2012 Apr 18.

12.

Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P.

Infect Immun. 1997 Aug;65(8):3328-36.

13.

Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.

Tumban E, Muttil P, Escobar CA, Peabody J, Wafula D, Peabody DS, Chackerian B.

Vaccine. 2015 Jun 26;33(29):3346-53. doi: 10.1016/j.vaccine.2015.05.016. Epub 2015 May 21.

14.

Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.

Hunter Z, Tumban E, Dziduszko A, Chackerian B.

Vaccine. 2011 Jun 20;29(28):4584-92. doi: 10.1016/j.vaccine.2011.04.051. Epub 2011 May 5.

15.

Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.

Hanumantha Rao N, Baji Babu P, Rajendra L, Sriraman R, Pang YY, Schiller JT, Srinivasan VA.

Vaccine. 2011 Oct 6;29(43):7326-34. doi: 10.1016/j.vaccine.2011.07.071. Epub 2011 Jul 29.

16.

HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.

Yan X, Wang D, Liang F, Fu L, Guo C.

Hum Vaccin Immunother. 2014;10(12):3491-8. doi: 10.4161/hv.36084.

17.

Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Tyler M, Tumban E, Dziduszko A, Ozbun MA, Peabody DS, Chackerian B.

Vaccine. 2014 Jul 23;32(34):4267-74. doi: 10.1016/j.vaccine.2014.06.054. Epub 2014 Jun 21.

18.

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RB, Christensen ND.

Vaccine. 2015 Oct 13;33(42):5553-63. doi: 10.1016/j.vaccine.2015.09.005. Epub 2015 Sep 15.

19.

An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.

Paz De la Rosa G, Monroy-García A, Mora-García Mde L, Peña CG, Hernández-Montes J, Weiss-Steider B, Gómez-Lim MA.

Virol J. 2009 Jan 6;6:2. doi: 10.1186/1743-422X-6-2.

Supplemental Content

Support Center